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A B S T R A C T
Background: : The severity of Obsessive-Compulsive Disorder (OCD) varies significantly among probands. No
study has specifically investigated the genetic base of OCD severity. A previous study from our group found an
OCD polygenic risk score to predict pre- and post-treatment severity. This study explores the genomic bases of
OCD severity.
Methods: : We administered the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) to 401 patients at their first
visit to our clinic to measure their OCD severity. Genotyping data was collected by using the Infinium
PsychArray-24 BeadChip kit (Illumina). We analyzed genetic association with OCD severity in a linear regression
analysis at single-nucleotide polymorphism (SNP)- and gene-levels, this last also considering rare variants.
Enrichment analyses were performed from gene-based analyses’ results.
Results: : No SNP reached significant association (p < 10−8) with the YBOCS. Six markers showed suggestive
association (p<10−5). The top SNP was an intergenic variant in chromosome 2: rs7578149 (p< 1.89 × 10−6),
located in a region suggestively associated with MDD. Linkage disequilibrium was found for two clusters of SNPs
located between SLC16A14 and SP110 in chromosome 2, all of them forming one peak of association.
Enrichment analyses revealed OCD genes to be associated with porin activity (FDR = 0.01) and transmembrane
structure (FDR = 0.04).
Limitations: : The size of the sample and the transversal nature of the severity measure are limitations of this
study.
Conclusion: : This study contributes to better characterize OCD at an individual level, helping to know more
about the prognosis of the disorder and develop more individualized treatments.
Introduction
Obsessive compulsive disorder (OCD) is a neuropsychiatric condi-
tion with an estimated prevalence of 2–3% (Richter and Ramos, 2018).
It may cause significant functional disability in daily life depending
partly on the severity of the disorder, which varies significantly from
one individual to another (Ruscio et al., 2010). Clinically, greater OCD
severity is associated with an earlier age of onset (Wang et al., 2012),
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lower response to pharmacological treatments (Tükel et al., 2006) and a
lower remission rate (Eisen et al., 2013). Biologically, familial OCD
(having relatives diagnosed with OCD) has been linked to greater dis-
ease severity compared to sporadic OCD (Arumugham et al., 2014). In
addition, neuroimaging studies have indicated that gray matter vo-
lumes within the left medial orbitofrontal cortex and left putamen
contain discriminative information for predicting OCD severity
(Hoexter et al., 2013). Since some of these clinical and biological
characteristics have been associated to specific genetic contribution
(Atmaca et al., 2011; Dickel et al., 2006; Real et al., 2013, 2009;
Samuels et al., 2011), it might suggest that genetic factors might con-
tribute to OCD severity.
Symptom severity has been shown to have a genetic component in
other psychiatric disorders. In schizophrenia (SCZ), three studies have
linked genetic variation to disease severity. For example, the severity of
chronic delusional syndrome has been associated with rs20544, which
is not a risk variant for SCZ (Lepeta et al., 2017), while more severe
SCZ, which is associated with greater symptom severity at a given
moment (Schennach et al., 2012), has been linked to heterozygosity of
the C677T polymorphism within MTHFR (Kevere et al., 2014). Fur-
thermore, telomere length has been reported to positively correlate
with symptom severity, discriminating between remitted and non-re-
mitted patients with SCZ (Maurya et al., 2018). A variant (rs0994359)
within ANK3, a gene related to bipolar disorder status, has been re-
ported to be suggestively associated with the severity of social anxiety
disorder (Forstner et al., 2017). In major depressive disorder (MDD),
the severity of the episodes has been linked to two polygenic risk scores
built from risk variants for MDD and bipolar disorder (Ferentinos et al.,
2014). Thus, all these findings provide further support for a potential
genetic basis of OCD severity.
In a previous study exploring the ability of a polygenic risk score
(PRS) to predict pharmacological treatment response in OCD patients,
we observed an association with baseline and post-treatment severity
(Alemany-Navarro et al., 2019), suggesting that genetic factors might
affect OCD severity independently of pharmacological treatment.
While candidate gene and genome-wide association studies (GWAS)
have identified risk variants for OCD within catecholaminergic, gluta-
matergic and neurotrophic genes (Mattheisen et al., 2015;
Stewart et al., 2013; Taylor, 2013), to our knowledge, there have been
no studies specifically assessing whether OCD severity might be asso-
ciated with genetic factors. The objective of this study was to explore
the possible genomic bases of OCD severity. Knowing more about the
genetic basis of OCD severity may help to know more about the prog-




Four hundred and one Spanish Caucasian patients (n = 401; 210
females; mean age = 35.09 ± 10.66 years) with diagnosed OCD for at
least one year were recruited from the OCD clinic at Bellvitge Hospital
(Barcelona, Spain). Diagnoses were made by two psychiatrists with
extensive clinical experience in OCD, following the DSM-IV criteria
(American Psychiatric Association, 1994) and using the Structured
Clinical Interview for DSM-IV Axis I Disorders - Clinician Version (SCID-
I) (First et al., 1996). Patients presenting psychoactive substance abuse/
dependence (current or in the past six months), psychotic disorders,
intellectual disability, severe organic or neurological pathology (except
tic disorders) or autism spectrum disorder (ASD) were excluded from
the study. Other affective and anxiety disorders were not criteria for
exclusion in the cases where OCD was the main diagnosis.
Patients were required to give their written informed consent after
being fully informed about the study. This study was approved by the
Ethical Committees of Bellvitge Hospital and was performed in
accordance with the Declaration of Helsinki.
Clinical assessment
Sociodemographic, clinical and medical data were collected
through a structured interview with each patient during their first ap-
pointment at our clinic.
The age at onset was defined as the moment when the obsessive
symptoms reached a clinically significant level. Family psychiatric
history was recorded as a dichotomous score, with specific information
on OCD, Tourette syndrome and depression also collected. Only family
members with a formal diagnosis were considered.
Baseline severity of the obsessive and compulsive symptoms was
assessed through the clinician-administered version of the Yale-Brown
Obsessive Compulsive Scale (Y-BOCS) (Goodman et al., 1989) during
the patient's first visit to our clinic. A global score, as well as separate
ones for the obsessions and compulsions, respectively, was recorded.
Genotyping data and quality control
Our initial sample consisted of 401 OCD patients, who were geno-
typed using the Infinium PsychArray-24 BeadChip kit (Illumina). This
array was developed in collaboration with the Psychiatric Genomics
Consortium (PGC) and includes 50,000 variants associated with
common psychiatric disorders. Variant calling was performed using
three different algorithms: GenCall, which is Illumina's default calling
algorithm, and Birdseed were used for common variants, while zCall
was applied for rare variants. A unique set of genotypes was made from
a consensus merge between the results from GenCall and Birdseed for
the common variants, also including the rare variants called by zCall.
Quality control filtering was carried out for the obtained genotype
data using PLINK (Purcell et al., 2007). Only non-monomorphic auto-
somal biallelic variants were analyzed. Markers with a genotype call
rate <98% or those showing clear deviation from the Hardy-Weinberg
equilibrium (HWE) (p < 0.0001) were discarded.
Samples with a call rate below 98% were removed. Identity by
descent was calculated using independent SNPs, filtering out those with
a pi-hat greater than 0.2 (Marees et al., 2018). Population stratification
was analyzed by principal component analysis, removing the samples
that were more than 5 standard deviations (sd) away from the mean in
the first two components.
Statistical analysis
SNP-level association analysis was performed using the GenABEL
library for R (Aulchenko et al., 2007). Association with OCD severity
was evaluated by linear regression analyses, using as dependent vari-
ables the global Y-BOCS score and the obsession and compulsion sub-
scale scores. In the regression model SNPs were coded under a log-
additive model (in which the genotypes were coded as 0, 1 or 2 in
relation to the number of minor alleles); age and sex were included as
covariates in the model. These analyses were performed for autosomal
SNPs (markers showing a minor allele frequency (MAF) > 0.05 in non-
sex chromosomes). Linkage disequilibrium (LD) plots were obtained
with the LocusZoom software, based on the 1000 Genomes CEU po-
pulation data (hg19/1000 Genomes Mar 2012 EUR) (Pruim et al.,
2010). For SNP annotation, we used the Infinium PsychArray Gene
Annotation File provided by Illumina (https://support.illumina.com/
downloads/infinium-psycharray-product-support-files.html).
Gene-based association analyses were performed with the Sequence
Kernel Association Test (SKAT) (Wu et al., 2011) using the SKATMeta
library (Voorman et al., 2013) for R to explore the cumulative effect of
SNPs and the rare variants of a given gene on OCD severity, using global
YBOCS score as the dependent variable. Only the results from genes
with at least two genotyped markers were considered. False discovery
rate (FDR) correction was used to determine statistical significance.
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Enrichment analyses were performed for the genes with at least two
genotyped markers and a SKAT p-value lower than 0.01, using web-
accessible DAVID (Database for Annotation, Visualization and
Integrated Discovery) Bioinformatics Resources v6.8 (Huang et al.,
2009a, b).
Results
Genotyping and quality control
After quality control, 376 samples remained. Table 1 presents the
sociodemographic and clinical data, including the Y-BOCS scores, of the
final sample (n = 376).
SNP-level association analyses
Our total data set consisted of 338,357 autosomal markers, of which
258,937 were SNPs (MAF ≥ 0.05). We found nominal (α = 0.05) as-
sociation for 13,661 SNPs. Among these, 335 had a p-value < 0.001
and 55 a p-value < 1 × 10−4. No SNP reached genome-wide sig-
nificance (p < 5× 10−8) or passed the multiple comparison correction
(p = 1.97 × 10−7). The SNP with the lowest p-value was an intergenic
variant within chromosome 2 (rs7578149, p= 1.89 × 10−6, β = 1.92;
SE = 0.40). There were 5 other SNPs showing suggestive association at
p < 1 × 10−5 (Lander, E., Kruglyak, 1995) (rs9615637, rs11924650,
rs6436908, rs229836 and rs7599478). Fig. 1 shows a ‘Manhattan plot’
(Fig. 1a) and a ‘Q-Q plot’ (Fig. 1b) of the association results for the
common variants under a log-additive model. Association values for the
top 55 SNPs (p < 1 × 10−4) are presented in Table 2. MAF values for
some of the top SNPs in cases (our sample) and two control populations
(Spanish DNA biobank and 1000g-EUR) are reported in Table S1. In
general terms, we did not observe a tendency towards a greater MAF in
cases for those SNPs positively associated (positive β coefficient) with
severity, or a lower MAF for the SNPs with a negative β coefficient - as it
could be expected.
Two of the top 55 SNPs, rs7599478 (p = 8.68 × 10−6, β = 1.86;
SE = 0.42) and rs6436908 (p = 7.94 × 10−6, β =−1.75; SE = 0.39),
occur in the same genomic region and have an intermediate LD
(r2 = 0.36; D’ = 1) between them, as reported by the LDlink database
(Machiela and Chanock, 2018, 2015). Both are in high LD with the
genotyped intergenic variants located between SP110 and SLC16A14
(rs6743476 (p = 2.72 × 10−5, β = 1.76; SE = 0.42) and rs12694840
(p = 9.29 × 10−5, β = 1.58; SE = 0.40); Fig. 2a and b). All these
markers should be considered as forming a single association peak,
since none of them maintained their level of association when adjusting
the model for the rest of the markers.
We then compared our top associated SNPs with those previously
linked to OCD, using the data available on the PGC website from two
case-control GWAS on OCD risk (Mattheisen et al., 2015; Stewart et al.,
2013). From a total of 8409,516 SNPs in the PGC data, 251,129 were
also present in our data. However, when selecting the variants with a p-
value of association below 1× 10−4 for both sets of data, there were no
remaining markers shared between our data and the PGC results.
We also tested for association with the obsession and compulsion
subscales separately to clarify if one of these showed greater genetic
weight. The Manhattan plots for both subscales are shown in
Supplementary Figures 1 and 2 (Figures S1 and S2). For the obsession
subscale, we observed associations for 13,117, 311 and 27 SNPs at the
nominal, p < 0.001 and p < 0.0001 levels, respectively, with two SNPs
showing suggestive association: rs6764121 (p = 9.41 × 10−6,
β = −1.14; SE = 0.26) and rs35647811 (p = 9.75 × 10−6,
β = −1.45; SE = 0.33) (Table S2). For the compulsion subscale, there
were 13,378, 294 and 36 SNPs at the nominal, p < 0.001 and
p < 0.0001 levels, respectively, with 4 presenting suggestive associa-
tion: rs6569819 (p = 4.19 × 10−6, β = 1.33; SE = 0.29), rs16876441
(p = 9.34 × 10−6, β = −2.76; SE = 0.62), rs1285950
(p = 3.94 × 10−6, β = −1.43; SE = 0.31) and rs2220130
(p = 9.21 × 10−6, β = −1.25; SE = 0.28) (Table S3).
Gene-based association analyses
Gene-based analyses were performed for 21,551 genes. Of these,
16,653 had at least two genotyped markers and were analyzed further.
Nominal association was shown by 882 genes, none of them passing the
multiple comparison correction. Results for the top 12 genes
(p < 0.001) are shown in Supplementary Table 4 (Table S4). The genes
with the lowest p-value were SLC8A1 (solute carrier family 8 member
A1; p = 1 × 10−4), MAP4K4 (mitogen-activated protein kinase 4;
p = 3 × 10−4), WTAP (WT1 associated protein; p = 2 × 10−4) and
SLC22A10 (solute carrier family 22 member A10; p = 1 × 10−4).
Functional annotation
After selecting those genes with at least two genotyped markers and
a SKAT p-value lower than 0.01, functional annotation was performed
for a final set of 161 genes - referred to as the OCD genes from now on.
The porin activity category was significantly enriched
(p = 8.0 × 10−4), passing multiple correction (FDR = 0.01), and was
represented by three genes: AQP9 (aquaporin 9), VDAC1 (voltage-de-
pendent anion channel 1) and TOMM40L (translocase of outer mi-
tochondrial membrane 40 like).
A substantial number of the OCD genes were included in the
transmembrane category, which presented a fold enrichment of 1.4,
reaching the multiple comparison threshold (p = 0.0032; FDR = 0.04).
This category included 56 of the OCD genes (35.9%).
The other enriched categories included MAPK signaling, specifically
the regulation of N-methyl-D-aspartate (NMDA) selective glutamate
receptor activity (fold enrichment = 25.8; p = 0.0058; FDR = 0.086),
which included three OCD genes (RASGRF1 (Ras-specific guanine nu-
cleotide-releasing factor 1), MAPK8IP2 (mitogen-activated protein ki-
nase 8 interacting protein 2) and MEF2C (myocyte enhancer factor
2C)). NOTCH signaling was also represented by three OCD genes (DLL4
Table 1
Sociodemographic and clinical characteristics of the sample of 376 OCD pa-
tients.
Age, years 35.15 ± 10.73 (18–71)
Male/Female 186/190 (49.47/ 50.53)
Age at onset of OCD 19.87 ± 8.98 (4–46)*
Y-BOCS score
Global 25.80 ± 5.53 (9–40)
Obsessions 12.62 ± 3.58 (0–20)
Compulsions 12.30 ± 3.96 (0- 20)
Baseline HDRS score 12.21 ± 5.97 (0–29)
Current comorbidity
No comorbidity 212 (56.38)
Mood disorder 71 (18.88)
Tics 52 (13.83)
Eating disorders 19 (05.05)







No psychiatric diagnosis 138 (36.70)
OCD 81 (21.54)
Mood disorder 114 (30.32)
Tics/ Tourette sydrome 35 (9.31)
OCD, obsessive compulsive disorder; Y-BOCS, Yale-Brown Obsessive
Compulsive Scale; HDRS, Hamilton Depression Rating Scale.
Data are mean± SD (range) or percentage (%).
⁎ Age at onset was collected for 374 patients (n = 374).
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(delta like canonical Notch ligand 4), UBC (ubiquitin C) and PSEN2
(presenilin 2)). Activation of the Notch 1 and Notch 2 pathways showed
nominal association (p = 0.025 and p = 0.013, respectively), dis-
playing an enrichment score of 11.9 and 17.2, respectively, but not
passing the multiple comparison correction (FDR = 0.16 and 0.29,
respectively).
Three of the OCD genes (MAPK8IP2, DPP4 (dipeptidyl peptidase 4)
and VDAC1) were nominally associated with the behavioral fear re-
sponse (p = 0.02), but they did not pass the multiple comparison
correction (FDR = 0.28).
Discussion
To our knowledge, this is the first study attempting to analyze
Fig. 1. Genome-wide association test of genetic variants and YBOCS scores (OCD global severity) (a) Manhattan plot for the association test. A blue line indicates the
level of suggestive evidence of association (1 × 10−5). (b) Q-Q plot for the association test.
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genetic associations of OCD severity, measured with the Y-BOCS
(Goodman et al., 1989), at the whole-genome level. Although further
research with a larger sample is needed, the present study contributes
to the understanding of how genetic variants may influence OCD se-
verity. Although no SNP reached genome-wide significance, six markers
showed suggestive association (p < 1 × 10−5), the top SNP being
rs7578149 (p < 1.89 × 10−6, β = 1.92; SE = 0.40) located between
RPS16P2 and LAPTM4A (42,896 and 60,649 bp, respectively). The as-
sociation analyses for the obsession and compulsion subscales revealed
rs6764121 (p = 9.41 × 10−6, β = −1.14; SE = 0.26; ATP13A4) and
rs1285950 (p = 3.94 × 10−6, β = −1.43; SE = 0.31; CLEC5A) as the
top SNPs, respectively. Gene-based analyses, which simultaneously
considered the effects of both rare and common variants, highlighted 12
genes that were suggestively associated (p < 0.001) with the Y-BOCS
scores. In this case, the top two significant genes belonged to the solute
carrier gene family (SLC8A1 and SLC22A10; p = 0.0001). Enrichment
analyses revealed that the OCD genes were associated with porin ac-
tivity (p = 8.0 × 10−4; FDR = 0.01) and transmembrane structure
(p = 0.0032; FDR = 0.04), and a trend of association with NMDA
activity regulation (p = 0.0058; FDR = 0.086), the NOTCH signaling
pathways (p= 0.025/0.013; FDR = 0.16/0.29) and the behavioral fear
response (p = 0.02; FDR = 0.28).
The top associated SNP (rs7578149) is located in a region reported
to have a marker suggestively associated with MDD in females
(rs7565124; p = 3.05 × 10−6) (Aragam et al., 2011). While there is no
LD between these two SNPs, as reported on the LDlink database
(Machiela and Chanock, 2018, 2015), they may both be associated with
differences in the expression of the same gene. We observed two more
Table 2
Results from the top SNPs associated with OCD severity from an additive model.
SNP N OR P Chr. Position Alleles Region Nearest gene (Distance in BP)
rs903908 374 −1.704501 1.57 × 10−05 1 2,202,967 [T/C] intronic SKI
rs260513 376 1.633388 3.86 × 10−05 1 2,180,524 [A/G] intronic SKI
rs7578149 376 1.917254 1.89 × 10−06 2 20,312,438 [A/C] intergenic RPS16P2 (42,896)
rs6436908 376 −1.754016 7.94 × 10−06 2 230,995,447 [T/C] intronic LOC107985997
rs7599478 376 1.8553 8.68 × 10−06 2 230,947,503 [A/C] intergenic SLC16A14 (13,788)
rs3771875 375 −1.783821 1.10 × 10−05 2 75,877,812 [A/G] intronic MRPL19
rs7591166 376 −1.841773 1.36 × 10−05 2 9,616,035 [A/G] intronic IAH1
rs7588344 376 −1.707379 2.23 × 10−05 2 75,846,558 T/C intergenic MRPL19 (49,734)
rs2422230 376 −1.607521 2.70 × 10−05 2 75,873,217 [T/C] regulatory region variant MRPL19 (692)
rs6743476 376 1.764152 2.72 × 10−05 2 230,992,756 [A/G] intergenic SP110 (40,878)
rs2001658 375 −1.758046 3.28 × 10−05 2 9,613,289 [T/C] intergenic CPSF3 (50)
rs11674954 376 1.940089 3.66 × 10−05 2 1,283,031 [T/G] intronic SNTG2
rs1048610 376 −1.721889 6.22 × 10−05 2 9,634,856 [A/G] exonic ADAM17
rs12694840 376 1.576828 9.29 × 10−05 2 230,997,403 [A/G] intergenic SP110 (36,231)
rs11924650 376 1.979962 6.00 × 10−06 3 54,258,938 [T/C] intronic CACNA2D3
rs870429 376 −1.780959 1.72 × 10−05 3 122,878,019 [A/G] intronic PDIA5
rs2227421 376 −1.670388 3.30 × 10−05 4 155,492,224 [A/C] exonic FGB
rs1495509 376 1.89329 5.11 × 10−05 4 21,393,616 [T/C] intronic KCNIP4
rs2648727 376 2.010023 5.34 × 10−05 5 52,074,401 [T/G] intergenic PELO (9373)
rs603852 376 1.590302 5.90 × 10−05 5 177,905,384 [T/G] intronic COL23A1
rs6884946 376 1.832425 8.80 × 10−05 5 122,899,301 [T/C] intronic CSNK1G3
rs10484428 375 1.640033 5.38 × 10−05 6 48,871,002 [A/C] intergenic LOC100418956 (48,704)
exm2270472 376 −1.958047 6.96 × 10−05 6 48,608,329 [T/C] intergenic LOC100418956 (311,377)
rs9296598 376 −1.973384 7.02 × 10−05 6 48,564,858 [A/G] intergenic RBMXP1 (322,153)
rs3010531 376 −1.954349 7.16 × 10−05 6 48,581,776 [T/C] intergenic LOC100418956 (337,930)
rs13191280 376 1.91115 8.63 × 10−05 6 66,491,725 [T/C] intergenic SLC25A51P1 (6047)
rs4299807 376 2.239835 8.99 × 10−05 6 66,528,177 [A/G] intergenic ADH5P4 (17,193)
rs6569819 376 −1.58711 9.51 × 10−05 6 132,963,041 [T/G] intergenic TAAR1 (3082)
rs7777145 376 2.832898 1.04 × 10−05 7 97,688,936 [T/C] intergenic LMTK2 (47,261)
kgp1254867 376 −1.823998 4.06 × 10−05 7 141,551,958 [T/C] intergenic ATP1A1OS (12,897)
rs4731231 376 1.953784 5.02 × 10−05 7 75,264,463 [A/G] intronic HIP1
rs1285950 376 −1.763092 5.33 × 10−05 7 141,636,563 [A/C] intronic CLEC5A
rs10464444 376 −1.799561 5.78 × 10−05 7 141,532,187 [A/G] intergenic PRSS37 (3891)
rs11765575 375 −1.792576 5.79 × 10−05 7 141,537,968 [A/G] intronic PRSS37
rs7794708 376 −1.749431 7.49 × 10−05 7 141,653,637 [T/C] intergenic CLEC5A (6854)
rs12534422 376 1.719212 9.61 × 10−05 7 75,263,792 [T/C] intronic HIP1
rs2719401 376 1.703063 3.42 × 10−05 8 55,198,858 [A/C] intergenic RNU105C
rs519761 376 1.75594 9.03 × 10−05 9 15,357,041 [T/C] intergenic RPL7P33 (4331)
rs776022 376 −1.652346 9.23 × 10−05 9 37,934,780 [T/C] intronic SHB
rs10815211 376 −1.960053 9.58 × 10−05 9 5,412,546 [T/C] intronic PLGRKT
rs10857636 376 −3.222238 2.41 × 10−05 10 49,985,110 [T/C] intronic WDFY4
exm2267086 376 2.012957 8.09 × 10−05 10 26,505,496 [A/G] exonic GAD2
rs4144614 376 −1.594181 5.10 × 10−05 11 95,742,703 [A/C] intronic MAML2
rs1575432 376 1.542177 7.70 × 10−05 13 61,212,933 [T/C] intergenic EIF4A1P6 (702)
rs229836 376 1.950295 8.17 × 10−06 14 83,867,535 [A/G] intergenic LOC100421611 (1597,087)
rs2626595 375 1.813838 1.68 × 10−05 14 97,956,267 [T/C] intergenic LOC101929241 (25,771)
rs11628827 376 2.001054 6.33 × 10−05 14 97,929,204 [A/C] intronic LOC101929241
rs1861085 376 1.924046 7.68 × 10−05 14 92,371,234 [T/C] intronic FBLN5
rs11647643 376 −1.840045 2.09 × 10−05 16 49,259,509 [T/C] intergenic CBLN1 (52,319)
rs12599955 375 1.653458 6.17 × 10−05 16 49,257,835 [T/C] intergenic CBLN1 (53,993)
rs321849 376 −1.657241 6.55 × 10−05 18 48,957,511 [A/G] intronic LOC100287225
rs321858 376 −1.637564 7.70 × 10−05 18 48,974,344 [T/C] intronic LOC100287225
rs10410689 376 −2.800791 1.80 × 10−05 19 51,769,145 [T/C] intronic SIGLECL1
rs6132764 376 −1.857997 1.43 × 10−05 20 24,752,226 [A/C] regulatory region variant SYNDIG1 (104,937)
rs9615637 376 −2.343338 2.36 × 10−06 22 48,184,882 [A/G] intronic LOC284930
SNP, single nucleotide polymorphism; Chr., chromosome number; OR, odds ratio; bp, base pairs.
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Fig. 2. Regional association plots with LD reported for suggestively associated (p < 10−5) single-nucleotide polymorphisms (SNPs) in chromosome 2. (a) Plot of
rs7599478 for the association test with the YBOCS (b) Plot of rs6436908.
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suggestively associated SNPs also in chromosome 2: rs6436908
(p = 7.94 × 10−6, β = −1.75; SE = 0.39) and rs7599478
(p = 8.68 × 10−6, β = 1.86; SE = 0.42). Of these, rs6436908 falls
within a GENCODE gene (LOC107985997) of unknown function and
has been described as an eQTL for both SLC16A14 in the liver and
SP110 in blood (Bonder et al., 2011; Lusis et al., 2008), with rs7599478
located between these two genes. SLC16A14 is a member of the
monocarboxylic acid transporter gene family, which is involved in en-
ergy metabolism, drug transport and T cell activation, and may also be
associated with memory and learning processes and neurodegenerative
diseases (Halestrap, 2013; Pérez-Escuredo et al., 2016). SP110, on the
other hand, is involved in immunological responses and transcription
regulation (Cliffe et al., 2012; Lei et al., 2012; Leu et al., 2018), with a
variant of this gene being reported to be associated with suicide
(rs181058279, p = 5.45 × 10−6) (Coon et al., 2018). Given the sug-
gestively associated SNPs near these two genes, as well as
LOC107985997 (rs6436908) and the LD findings for this region (Fig. 2),
it would be interesting to perform further research on this whole
genomic domain to elucidate the genetic bases of OCD severity.
The three other SNPs with suggestive association were: rs229836
(p = 8.17 × 10−6, β = 1.95; SE = 0.44), an intergenic variant located
between the two pseudogenes LOC100421611 and RNU7-51P that do
not have relevant information available; rs11924650
(p= 6.00 × 10−6, β= 1.98; SE = 0.44), a SNP in an intronic region of
CACNA2D3, a gene that has been suggestively associated with schizo-
phrenia and schizoaffective disorders (rs9311525, p = 1.03 × 10−5),
antipsychotic response, Alzheimer's disease (AD) (rs7431992,
p = 2.00 × 10−6) and child development disorders (rs1467179,
p = 6.17 × 10−5) (Li et al., 2017; Moons et al., 2016; Tosto et al.,
2015); and rs9615637 (p = 2.36 × 10−6, β = −2.34; SE = 0.50)
located in LOC284930, a gene linked to paliperidone response in schi-
zophrenic patients (rs147466853; p = 2.00 × 10−6) (Li et al., 2017).
The top SNPs for the obsession and compulsion subscales were two
intronic variants within ATP13A4 and CLEC5A, respectively. The first,
which encodes an ATPase protein, has been linked to impaired lan-
guage acquisition, dyslexia and an increased risk for ASD
(Biamino et al., 2015; Kwasnicka-crawford et al., 2005;
Vallipuram et al., 2010; Worthey et al., 2013). The second, although
not directly associated with any neuropsychiatric condition, is involved
in functions that have been previously reported to be associated with
OCD (Renna et al., 2018; Rodríguez et al., 2017; Uhl and
Martinez, 2019; Vilboux et al., 2016; Zamanian-azodi et al., 2018), such
as cell adhesion, cell-cell signaling, inflammation and immune re-
sponses (Batliner et al., 2011; Gupta et al., 2010; Teng et al., 2016).
Enrichment analyses revealed that porin activity was significantly
represented by three of our OCD genes: AQP9, VDAC1 and TOMM40L.
Porins are integral membrane proteins that function as pores through
which different molecules can enter or leave a cell. Efficient porin ac-
tivity is needed for optimal gradient concentrations and water home-
ostasis, which are essential for correct brain functioning (Min and van
der Knaap, 2018). In fact, VDAC1 has been suggested to be relevant in
the pathogenesis and pathophysiology of AD (Ferrer, 2009;
Manczak et al., 2013; Manczak and Reddy, 2013), while TOMM40L is
associated with different neurological conditions such as amyotrophic
lateral sclerosis, AD, frontotemporal lobar degeneration, Parkinson's
disease and dementia, as well as with non-pathological cognitive aging
(Heinemeyer et al., 2018). Meanwhile, AQP9 has been observed to be
involved in neuronal damage in an in vitro Parkinson's disease model
(Avola et al., 2018).
It is interesting to note that 35.9% of our OCD genes (56 out of 161)
are related to transmembrane structure and functioning (p = 0.0032;
FDR = 0.04), with the three genes associated with porin activity also
included in this functional category. The role of transmembrane pro-
teins in different neurodevelopmental and neuropsychiatric disorders
has been widely reported (Cao and Tabuchi, 2017; Eggert et al., 2018;
Kasem et al., 2018). Some of the OCD genes included in this category
have been previously suggested to be involved in different psychiatric
disorders and neurological conditions (Gai et al., 2016; Krohn et al.,
2011; Murray and Zhou, 2017; Schumacher et al., 2012).
Our results also indicated that the regulation of NMDA activity
might be associated with OCD as there was also an overrepresentation
of OCD genes in this category (p = 0.0058; FDR = 0.086), which in-
cluded RASGRF1, MPK8IP2 and MEF2C. The involvement of glutama-
tergic activity, specifically NMDA receptor activity, in OCD has been
well established (Albelda et al., 2010; Alonso et al., 2012; Mataix-
Cols et al., 2017).
Three of the OCD genes were associated with NOTCH signaling
pathways (DLL4, UBC and PSEN2) (Activation of Notch 1: p = 0.025,
FDR = 0.16; Activation of Notch 2: p = 0.013, FDR = 0.29). NOTCH
signaling has been linked to dopaminergic responsiveness in the
striatum (Toritsuka et al., 2017). Disturbed NOTCH signaling has been
observed in schizophrenia and bipolar disorder (Hoseth et al., 2018). In
the adult central nervous system, NOTCH signaling in brain regions
such as the basolateral amygdala and hippocampus seems to be in-
volved in instrumental conditioning and fear-related learning through
the modulation of synaptic plasticity (Dias Brian George et al., 2014;
Yoon et al., 2012). These results, together with the three OCD genes
associated with the behavioral fear response (MAPK8IP2, DPP4 and
VDAC1), support the implication of the fear response dysfunction ob-
served in OCD (Dougherty et al., 2018).
This study has some strengths to be noted. Our study cohort was
thoroughly characterized phenotypically and our results, although only
exploratory, are encouraging, highlighting several relevant pathways
and providing suggestive evidence of linkage for some interesting
genes. In addition, given the growing importance of rare variants in
neuropsychiatry, their effect in addition to those of the common var-
iants were considered in the gene-based analyses (Ament et al., 2015;
Amin et al., 2018; Singh et al., 2017).
Limitations
Although we obtained interesting results passing multiple compar-
ison correction in the enrichment analyses, we think the lack of findings
reaching whole-genome significance at SNP-level analyses might be due
in part to our sample size (n = 376). Since this study conforms a very
exploratory analysis on the genomic bases of OCD severity, we think a
larger sample might be required in order to obtain some positive results
at this level of analysis. In addition, our OCD severity measure does not
report a whole course severity, but rather a transversal measure of the
severity. Longitudinal variables accounting for the course of the dis-
order, such as worst-ever period severity, might be important to elu-
cidate the genetic influences on OCD severity. Similar approaches with
larger sample sizes will help unravel the genetic influences on OCD
severity.
Conclusions
The relevance of this study is through its contribution in better
characterizing OCD at an individual level, which might help in knowing
more about the prognosis of the disorder and developing more in-
dividualized treatments. Further research with larger samples and dif-
ferent methodologies is needed. Moreover, next-generation sequencing
could provide more information on the rare variants and de novo mu-
tations that might be involved in OCD severity.
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